Page 896 - Read Online
P. 896
Page 14 of 14 Cullen et al. Hepatoma Res 2020;6:76 I http://dx.doi.org/10.20517/2394-5079.2020.69
results from an observational retrospective study. Cancer Chemother. Pharmacol 2020;86:129-39.
58. Lee MS, RyooBY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an
open-label, multicentre, phase 1b study. Lancet Oncol 2020;21:808-20.
59. Kim R, Tan E, Wang E, et al. A phase i trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer.
Oncologist 2020; doi: 10.1634/theoncologist.2020-0759.
60. Berenguer M, Burra P, Ghobrial M, et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular
carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;1143-9.
61. Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma. Ann Surg
2017;265:557-64.
62. Lee JH, Cho Y, Kim HY, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for
hepatocellular carcinoma patients beyond the milan criteria. Ann Surg 2016;263:842-50.
63. Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for
hepatocellular carcinoma. Gastroenterology 2018;154:128-39.
